| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antifungal Agents | 23 | 2019 | 1828 | 3.42 | Why? |
| Invasive Fungal Infections | 9 | 2019 | 274 | 2.03 | Why? |
| Mycoses | 7 | 2019 | 589 | 1.86 | Why? |
| Triazoles | 8 | 2019 | 440 | 1.81 | Why? |
| Drug Resistance, Fungal | 5 | 2018 | 191 | 1.47 | Why? |
| Hematologic Neoplasms | 13 | 2020 | 2105 | 1.36 | Why? |
| Invasive Pulmonary Aspergillosis | 4 | 2021 | 634 | 1.16 | Why? |
| Leukemia, Myeloid, Acute | 6 | 2020 | 676 | 1.10 | Why? |
| Candida | 5 | 2019 | 425 | 1.05 | Why? |
| Aspergillus fumigatus | 6 | 2019 | 239 | 0.93 | Why? |
| Aspergillosis | 7 | 2019 | 264 | 0.93 | Why? |
| Odontoid Process | 1 | 2019 | 6 | 0.81 | Why? |
| Chondrocalcinosis | 1 | 2019 | 13 | 0.79 | Why? |
| Candidemia | 4 | 2018 | 353 | 0.76 | Why? |
| Central Nervous System Fungal Infections | 2 | 2018 | 17 | 0.72 | Why? |
| Neck Pain | 1 | 2019 | 126 | 0.69 | Why? |
| Drug Resistance, Multiple, Fungal | 2 | 2018 | 45 | 0.69 | Why? |
| Yeasts | 1 | 2017 | 50 | 0.68 | Why? |
| Echinocandins | 3 | 2017 | 139 | 0.68 | Why? |
| Mannans | 1 | 2018 | 218 | 0.68 | Why? |
| Mucorales | 2 | 2018 | 92 | 0.66 | Why? |
| Fungi | 4 | 2019 | 471 | 0.66 | Why? |
| Nausea | 1 | 2020 | 457 | 0.66 | Why? |
| Nitriles | 4 | 2019 | 1053 | 0.66 | Why? |
| Calcinosis | 1 | 2019 | 240 | 0.62 | Why? |
| Voriconazole | 4 | 2018 | 206 | 0.62 | Why? |
| Serum | 1 | 2018 | 294 | 0.61 | Why? |
| Vomiting | 1 | 2020 | 722 | 0.58 | Why? |
| Azoles | 3 | 2019 | 185 | 0.57 | Why? |
| Pyridines | 3 | 2019 | 680 | 0.55 | Why? |
| Candidiasis | 2 | 2019 | 334 | 0.54 | Why? |
| Immunocompromised Host | 6 | 2019 | 5150 | 0.53 | Why? |
| Mucormycosis | 4 | 2018 | 832 | 0.52 | Why? |
| Ascomycota | 1 | 2014 | 71 | 0.52 | Why? |
| Chemoprevention | 2 | 2018 | 585 | 0.52 | Why? |
| Pulmonary Aspergillosis | 1 | 2018 | 408 | 0.51 | Why? |
| False Positive Reactions | 1 | 2018 | 1338 | 0.51 | Why? |
| Kidney Transplantation | 3 | 2021 | 5397 | 0.47 | Why? |
| Leukemia | 2 | 2018 | 598 | 0.44 | Why? |
| Apoptosis | 2 | 2017 | 2335 | 0.42 | Why? |
| Drug Delivery Systems | 3 | 2019 | 1365 | 0.40 | Why? |
| Drosophila melanogaster | 3 | 2019 | 85 | 0.40 | Why? |
| GATA2 Transcription Factor | 1 | 2019 | 13 | 0.39 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.39 | Why? |
| Ursidae | 1 | 2018 | 9 | 0.38 | Why? |
| Rhizopus | 1 | 2018 | 32 | 0.38 | Why? |
| Pyrazoles | 3 | 2018 | 1791 | 0.37 | Why? |
| Antimicrobial Stewardship | 1 | 2017 | 931 | 0.37 | Why? |
| Dermatomycoses | 1 | 2019 | 55 | 0.37 | Why? |
| Meningitis, Fungal | 1 | 2018 | 17 | 0.37 | Why? |
| Checkpoint Kinase 1 | 1 | 2017 | 10 | 0.37 | Why? |
| Wound Infection | 1 | 2019 | 66 | 0.37 | Why? |
| Parasitic Diseases | 1 | 2019 | 84 | 0.37 | Why? |
| Aspergillus nidulans | 1 | 2017 | 2 | 0.36 | Why? |
| Transplant Recipients | 3 | 2020 | 4982 | 0.36 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.36 | Why? |
| Glycols | 1 | 2017 | 9 | 0.36 | Why? |
| Iron | 2 | 2018 | 619 | 0.36 | Why? |
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 37 | 0.36 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.35 | Why? |
| Coccidioidomycosis | 1 | 2018 | 47 | 0.35 | Why? |
| Zygomycosis | 2 | 2008 | 8 | 0.35 | Why? |
| Orbital Cellulitis | 1 | 2017 | 27 | 0.35 | Why? |
| Candida parapsilosis | 1 | 2017 | 34 | 0.35 | Why? |
| Fumarates | 1 | 2017 | 38 | 0.35 | Why? |
| Protein Kinase Inhibitors | 2 | 2018 | 1585 | 0.34 | Why? |
| Aspergillus | 2 | 2018 | 347 | 0.34 | Why? |
| Consultants | 1 | 2017 | 69 | 0.34 | Why? |
| Neutropenia | 2 | 2018 | 388 | 0.33 | Why? |
| Succinates | 1 | 2017 | 79 | 0.33 | Why? |
| Polyesters | 1 | 2017 | 94 | 0.33 | Why? |
| Cryptococcosis | 1 | 2018 | 97 | 0.32 | Why? |
| Eye Infections, Bacterial | 1 | 2017 | 86 | 0.32 | Why? |
| Tertiary Healthcare | 2 | 2018 | 616 | 0.31 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 2984 | 0.31 | Why? |
| Osteomyelitis | 1 | 2017 | 131 | 0.30 | Why? |
| Tissue Engineering | 1 | 2017 | 190 | 0.30 | Why? |
| Brain Diseases | 1 | 2018 | 1463 | 0.30 | Why? |
| Microbial Sensitivity Tests | 6 | 2019 | 2886 | 0.30 | Why? |
| Pyrimidines | 3 | 2018 | 1557 | 0.30 | Why? |
| Cyclonic Storms | 1 | 2019 | 236 | 0.30 | Why? |
| Stem Cell Transplantation | 2 | 2018 | 531 | 0.30 | Why? |
| Neoplasms | 8 | 2021 | 17251 | 0.28 | Why? |
| Cardiac Tamponade | 1 | 2018 | 165 | 0.28 | Why? |
| Antibodies, Neoplasm | 1 | 2003 | 15 | 0.27 | Why? |
| Macrophages, Alveolar | 1 | 2018 | 668 | 0.27 | Why? |
| Melanins | 2 | 2018 | 42 | 0.27 | Why? |
| Myeloproliferative Disorders | 1 | 2019 | 507 | 0.27 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.26 | Why? |
| Wound Healing | 1 | 2017 | 424 | 0.26 | Why? |
| Arthritis | 1 | 2017 | 288 | 0.26 | Why? |
| Methylprednisolone | 1 | 2014 | 2107 | 0.25 | Why? |
| Quinolines | 1 | 2017 | 403 | 0.25 | Why? |
| Tablets | 2 | 2018 | 219 | 0.25 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.24 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 526 | 0.24 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2018 | 877 | 0.24 | Why? |
| Fluconazole | 2 | 2017 | 145 | 0.24 | Why? |
| Pericarditis | 1 | 2018 | 417 | 0.23 | Why? |
| Cytomegalovirus Infections | 1 | 2018 | 667 | 0.23 | Why? |
| Pneumonia | 2 | 2020 | 5652 | 0.23 | Why? |
| Gastrointestinal Microbiome | 2 | 2020 | 1961 | 0.23 | Why? |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 31 | 0.21 | Why? |
| Disasters | 1 | 2019 | 760 | 0.21 | Why? |
| Humans | 65 | 2021 | 930598 | 0.20 | Why? |
| Middle Aged | 34 | 2021 | 270681 | 0.20 | Why? |
| Lung Diseases, Fungal | 1 | 2011 | 167 | 0.20 | Why? |
| Rhodotorula | 1 | 2018 | 4 | 0.20 | Why? |
| Hematopoietic Stem Cell Transplantation | 5 | 2018 | 2426 | 0.20 | Why? |
| Calmodulin | 1 | 2018 | 15 | 0.19 | Why? |
| Lymphoma, B-Cell | 1 | 2020 | 166 | 0.19 | Why? |
| Lymphocyte Depletion | 1 | 2020 | 293 | 0.19 | Why? |
| Sirolimus | 1 | 2021 | 240 | 0.19 | Why? |
| Male | 38 | 2021 | 367725 | 0.18 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.18 | Why? |
| Galactose | 1 | 2018 | 201 | 0.18 | Why? |
| Environmental Exposure | 1 | 2019 | 1558 | 0.18 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.18 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2021 | 385 | 0.18 | Why? |
| Polyenes | 1 | 2017 | 16 | 0.18 | Why? |
| Lymphoma | 1 | 2003 | 522 | 0.18 | Why? |
| Brucellosis | 1 | 2018 | 49 | 0.18 | Why? |
| Cervical Vertebrae | 1 | 2019 | 151 | 0.17 | Why? |
| Tacrolimus | 1 | 2021 | 435 | 0.17 | Why? |
| Candida glabrata | 1 | 2017 | 50 | 0.17 | Why? |
| Phenotype | 1 | 2019 | 4037 | 0.17 | Why? |
| Antineoplastic Agents | 3 | 2018 | 3550 | 0.17 | Why? |
| Animals | 15 | 2019 | 78931 | 0.17 | Why? |
| Microtubule-Associated Proteins | 1 | 2018 | 187 | 0.16 | Why? |
| Serologic Tests | 2 | 2018 | 4359 | 0.16 | Why? |
| Salvage Therapy | 2 | 2006 | 417 | 0.16 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.16 | Why? |
| Disease Models, Animal | 6 | 2019 | 10998 | 0.16 | Why? |
| Signal Transduction | 3 | 2018 | 7207 | 0.16 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.15 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.15 | Why? |
| Amphotericin B | 1 | 2017 | 256 | 0.15 | Why? |
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 334 | 0.15 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.15 | Why? |
| Female | 34 | 2021 | 380317 | 0.15 | Why? |
| Aged | 24 | 2021 | 215776 | 0.15 | Why? |
| Adenine | 2 | 2018 | 463 | 0.14 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1573 | 0.14 | Why? |
| Anti-Inflammatory Agents | 1 | 2014 | 6153 | 0.14 | Why? |
| Drug Utilization | 1 | 2020 | 619 | 0.14 | Why? |
| Bone Marrow | 1 | 2007 | 492 | 0.13 | Why? |
| Adult | 23 | 2021 | 244371 | 0.13 | Why? |
| Genetic Predisposition to Disease | 1 | 2019 | 4027 | 0.13 | Why? |
| Administration, Intravenous | 2 | 2017 | 1115 | 0.13 | Why? |
| Calcium | 1 | 2018 | 708 | 0.12 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.12 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.12 | Why? |
| Clinical Trials as Topic | 3 | 2021 | 7330 | 0.12 | Why? |
| Survival Analysis | 5 | 2018 | 7592 | 0.12 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.12 | Why? |
| Young Adult | 11 | 2019 | 93724 | 0.12 | Why? |
| Virus Diseases | 1 | 2019 | 3779 | 0.11 | Why? |
| RNA, Ribosomal, 16S | 2 | 2020 | 793 | 0.11 | Why? |
| Piperidines | 2 | 2018 | 795 | 0.11 | Why? |
| Clinical Laboratory Techniques | 1 | 2018 | 23402 | 0.11 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.11 | Why? |
| Transplantation, Homologous | 2 | 2018 | 757 | 0.11 | Why? |
| Heart-Assist Devices | 1 | 2019 | 812 | 0.11 | Why? |
| Aged, 80 and over | 10 | 2019 | 88759 | 0.11 | Why? |
| Polymerase Chain Reaction | 2 | 2020 | 6740 | 0.11 | Why? |
| In Vitro Techniques | 1 | 2014 | 1027 | 0.10 | Why? |
| Retrospective Studies | 13 | 2021 | 105322 | 0.10 | Why? |
| Risk Factors | 12 | 2021 | 71621 | 0.10 | Why? |
| Models, Theoretical | 1 | 2019 | 6659 | 0.10 | Why? |
| Graft Rejection | 1 | 2021 | 1766 | 0.10 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.10 | Why? |
| Induction Chemotherapy | 1 | 2020 | 149 | 0.10 | Why? |
| Spores, Fungal | 1 | 2018 | 23 | 0.10 | Why? |
| Texas | 2 | 2019 | 1237 | 0.10 | Why? |
| Rhode Island | 2 | 2021 | 425 | 0.10 | Why? |
| Predictive Value of Tests | 2 | 2019 | 9537 | 0.10 | Why? |
| Organ Transplantation | 2 | 2018 | 2616 | 0.10 | Why? |
| Phagosomes | 1 | 2018 | 32 | 0.09 | Why? |
| Animals, Genetically Modified | 1 | 2019 | 230 | 0.09 | Why? |
| Germ-Line Mutation | 1 | 2019 | 86 | 0.09 | Why? |
| Cell Wall | 1 | 2018 | 62 | 0.09 | Why? |
| Headache | 1 | 2019 | 2257 | 0.09 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.09 | Why? |
| Mutation | 1 | 2019 | 12376 | 0.09 | Why? |
| Wettability | 1 | 2017 | 8 | 0.09 | Why? |
| Lepidoptera | 1 | 2017 | 26 | 0.09 | Why? |
| Compressive Strength | 1 | 2017 | 16 | 0.09 | Why? |
| CTLA-4 Antigen | 1 | 2019 | 282 | 0.09 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.09 | Why? |
| Candida albicans | 1 | 2019 | 217 | 0.09 | Why? |
| Ergosterol | 1 | 2017 | 25 | 0.09 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.09 | Why? |
| Virulence | 2 | 2019 | 2172 | 0.08 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.08 | Why? |
| Molecular Weight | 1 | 2017 | 249 | 0.08 | Why? |
| Biocompatible Materials | 1 | 2019 | 214 | 0.08 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.08 | Why? |
| Debridement | 1 | 2017 | 172 | 0.08 | Why? |
| Cytochrome P-450 Enzyme System | 1 | 2017 | 144 | 0.08 | Why? |
| Fungal Proteins | 1 | 2017 | 133 | 0.08 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.08 | Why? |
| Phagocytosis | 2 | 2018 | 409 | 0.08 | Why? |
| Candidiasis, Invasive | 1 | 2017 | 107 | 0.08 | Why? |
| Disease Management | 3 | 2019 | 6841 | 0.08 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.07 | Why? |
| Tertiary Care Centers | 4 | 2018 | 8248 | 0.07 | Why? |
| Tissue Scaffolds | 1 | 2017 | 174 | 0.07 | Why? |
| Genetic Association Studies | 1 | 2019 | 559 | 0.07 | Why? |
| Biopsy | 2 | 2019 | 2811 | 0.07 | Why? |
| Drug Compounding | 1 | 2017 | 386 | 0.07 | Why? |
| Fever | 2 | 2019 | 7795 | 0.07 | Why? |
| Mice, Inbred BALB C | 2 | 2019 | 5814 | 0.07 | Why? |
| Light | 1 | 2017 | 306 | 0.07 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 449 | 0.07 | Why? |
| Microbial Viability | 1 | 2018 | 406 | 0.07 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2019 | 724 | 0.07 | Why? |
| Leukemia, Prolymphocytic | 1 | 2003 | 10 | 0.07 | Why? |
| Kidney Failure, Chronic | 1 | 2021 | 3222 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.07 | Why? |
| Coinfection | 2 | 2021 | 6820 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Antibodies, Monoclonal | 1 | 2003 | 8041 | 0.07 | Why? |
| Cohort Studies | 4 | 2019 | 36005 | 0.07 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.07 | Why? |
| Adolescent | 8 | 2019 | 86841 | 0.06 | Why? |
| Alemtuzumab | 1 | 2003 | 121 | 0.06 | Why? |
| Alleles | 1 | 2019 | 1557 | 0.06 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.06 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.06 | Why? |
| Metabolomics | 1 | 2018 | 921 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2020 | 3893 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2019 | 6551 | 0.06 | Why? |
| Surgical Wound Infection | 1 | 2017 | 501 | 0.06 | Why? |
| Liver Function Tests | 1 | 2018 | 1325 | 0.06 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.06 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.06 | Why? |
| Physicians | 1 | 2021 | 4214 | 0.06 | Why? |
| Gene Expression Regulation | 2 | 2018 | 4020 | 0.06 | Why? |
| Feces | 2 | 2020 | 4235 | 0.05 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.05 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.05 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.05 | Why? |
| Tachypnea | 1 | 2021 | 197 | 0.05 | Why? |
| Flow Cytometry | 1 | 2019 | 2393 | 0.05 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.05 | Why? |
| Polymorphism, Genetic | 1 | 2017 | 1074 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Mice | 3 | 2019 | 21357 | 0.05 | Why? |
| Global Health | 2 | 2017 | 13911 | 0.05 | Why? |
| Disease Outbreaks | 1 | 2018 | 27595 | 0.05 | Why? |
| Genes, Insect | 1 | 2008 | 7 | 0.05 | Why? |
| Lung | 1 | 2018 | 31049 | 0.05 | Why? |
| Hyphae | 1 | 2008 | 22 | 0.05 | Why? |
| Leukocyte Count | 1 | 2019 | 3178 | 0.05 | Why? |
| Central America | 1 | 2018 | 86 | 0.05 | Why? |
| Lipopeptides | 1 | 2011 | 229 | 0.05 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.05 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.05 | Why? |
| Sleep Stages | 1 | 2018 | 52 | 0.05 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.04 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.04 | Why? |
| Drosophila Proteins | 1 | 2008 | 67 | 0.04 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.04 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.04 | Why? |
| Gene Expression | 1 | 2019 | 3332 | 0.04 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.04 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.04 | Why? |
| Hypotension | 1 | 2021 | 392 | 0.04 | Why? |
| Phagocytes | 1 | 2008 | 180 | 0.04 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.04 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.04 | Why? |
| Calcium Signaling | 1 | 2018 | 133 | 0.04 | Why? |
| Autophagy-Related Proteins | 1 | 2018 | 157 | 0.04 | Why? |
| Skin | 1 | 2019 | 2096 | 0.04 | Why? |
| Drug Evaluation, Preclinical | 1 | 2019 | 3347 | 0.04 | Why? |
| Antimicrobial Cationic Peptides | 1 | 2008 | 159 | 0.04 | Why? |
| Genotype | 1 | 2019 | 4697 | 0.04 | Why? |
| South America | 1 | 2018 | 565 | 0.04 | Why? |
| Immunotherapy | 1 | 2019 | 2421 | 0.04 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.04 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Endoplasmic Reticulum | 1 | 2018 | 430 | 0.04 | Why? |
| Liver | 1 | 2019 | 4007 | 0.04 | Why? |
| Time Factors | 2 | 2019 | 31397 | 0.04 | Why? |
| Medical Records | 1 | 2007 | 513 | 0.03 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.03 | Why? |
| HIV Infections | 1 | 2020 | 11620 | 0.03 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.03 | Why? |
| Analysis of Variance | 1 | 2007 | 950 | 0.03 | Why? |
| Child | 5 | 2018 | 70012 | 0.03 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.03 | Why? |
| Cancer Survivors | 1 | 2021 | 588 | 0.03 | Why? |
| Child, Preschool | 3 | 2018 | 36283 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.03 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.03 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.03 | Why? |
| Autophagy | 1 | 2018 | 960 | 0.03 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.03 | Why? |
| Infant | 2 | 2018 | 30274 | 0.03 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.03 | Why? |
| Pain | 1 | 2018 | 1084 | 0.02 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.02 | Why? |
| Heart Transplantation | 1 | 2019 | 1293 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Survival Rate | 1 | 2003 | 9206 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.02 | Why? |
| Dexamethasone | 1 | 2008 | 2055 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Sleep Wake Disorders | 1 | 2018 | 1463 | 0.02 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.02 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2018 | 3088 | 0.02 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.02 | Why? |
| Hospitals, University | 1 | 2018 | 4173 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Sleep | 1 | 2018 | 2695 | 0.02 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2008 | 4002 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Zoonoses | 1 | 2018 | 3034 | 0.02 | Why? |
| Symptom Assessment | 1 | 2018 | 4967 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| United States | 2 | 2020 | 46150 | 0.02 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Triage | 1 | 2021 | 7151 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2003 | 9335 | 0.01 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.01 | Why? |
| Saliva | 1 | 2017 | 4679 | 0.01 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.01 | Why? |
| Research Design | 1 | 2006 | 5830 | 0.01 | Why? |
| Travel | 1 | 2018 | 7220 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Infection Control | 1 | 2018 | 23131 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2021 | 15421 | 0.01 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| China | 1 | 2018 | 50654 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |